A Phase 2 interventional study of APL-130277 and APO-go in Parkinson Disease, sponsored by Sumitomo Pharma America, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-13.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing apomorphine in Parkinson Disease — 1 open to participants now, 2 under way, 1 of them phase 3. Apomorphine · Parkinson Disease.
Among the 32 studies testing apomorphine in Parkinson Disease, this one is the 30th largest by enrollment, is one of 5 that started in 2017, is one of 10 in phase 2, and was the 27th registered.
4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →1 of the 32 studies testing apomorphine in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–89
By country, each count listing its studies:
Apomorphine: first FDA approval 2004 (APOKYN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 14 · Phase 4 5
First in 1999; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 40 across 3,358 interventional studies indexed under Parkinson Disease.
Median enrollment 42 across the 32 interventional studies. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 8 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing apomorphine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated by "OFF" episodes.
This multi-center study will aim to evaluate the pharmacokinetics (PK) and comparative bioavailability of a single dose of APL-130277 sublingual thin film with subcutaneous (s.c.) APO-go® and s.c. APOKYN® in subjects with Parkinson's disease (PD). The dose of APOKYN® (≤ 5 mg) will be based on the subjects' current prescribed dose. The study is designed as an open-label, randomized, three-way crossover. Subjects will receive all three treatment arms with a minimum 1-day wash-out between each visit (excluding the screening visit) and will be randomly assigned to one of the six sequences
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female and of , must agree to use one of the following methods of :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
APL-130277, sublingual thin film, once daily
Drug: APL-130277
Subcutaneous APO-go, once daily
Drug: APO-go
Subcutaneous APOKYN, once daily
Drug: Apokyn
APL-130277 sublingual thin film
Also known as: amomorphine
Subcutaneous APO-go
Also known as: amomorphine
Subcutaneous APOKYN
Also known as: amomorphine
Maximum Observed Plasma Concentration (Cmax)
Dose normalized maximum observed plasma concentration (Cmax)
Time frame: Day 1
Observed Time of the Maximum Concentration (Tmax)
Time from dosing to Cmax, observed by inspection of individual subject plots of plasma concentration versus time.
Time frame: Day 1
Area Under the Concentration- Time Curve (AUC Last)
area under the concentration-time curve from time zero to the last measurable plasma concentration-time curve using the linear up log down trapezoidal rule.
Time frame: Day 1
Area Under the Concentration- Time Curve (AUC Inf)
area under the concentration-time curve from time zero extrapolated to infinity using the linear up log down trapezoidal rule.
Time frame: Day 1
Mean Residence Time (MRT)
Mean residence time during one dosing interval calculated using the following equation: MRT = AUMCinf/AUC inf. AUMCinf is the area under the first moment (time.plasma concentration vs. time) curve.
Time frame: Day 1
Metabolite/Parent (M/P) Drug Concentration Ratio -Cmax
Metabolite (apomorphine sulfate) to Parent exposure ratio, Cmax, corrected for molecular weight differences.
Time frame: Day 1
Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)
Apparent total clearance of the drug from plasma extravascular administration, calculated as Dose/AUCinf.
Time frame: Day 1
Apparent Volume of Distribution After Non-intravenous Administration (V/F)
Apparent volume of distribution after extravascular administration, calculated as Dose/(AUCinf \* λz).
Time frame: Day 1
Terminal-phase Half-life (t½)
Terminal phase half-life, as calculated by the following equation: t½ = ln(2)/λz.
Time frame: Day 1
Terminal-phase Rate Constant ( λz)
Apparent terminal elimination rate constant, determined by log linear regression of the plasma concentration versus time data that was judged to be in the log-linear elimination phase. At least 3 data points in the terminal phase will be used in the determination of the rate constant.
Time frame: Day 1
Metabolite/Parent (M/P) Drug Concentration Ratio -AUC Last
Metabolite (apomorphine sulfate) to Parent exposure ratio, AUClast, corrected for molecular weight differences.
Time frame: Day 1
| Milestone | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 1 | 1 | 2 |
| Completed | 1 | 1 | 2 | 1 | 1 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 1 | 1 | 2 |
| Completed | 1 | 1 | 2 | 1 | 1 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 1 | 1 | 2 |
| Completed | 1 | 1 | 2 | 1 | 1 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 1 | 1 | 2 |
| Completed | 1 | 0 | 2 | 1 | 1 | 2 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 |
|---|---|---|---|---|---|---|
| Started | 1 | 0 | 2 | 1 | 1 | 2 |
| Completed | 1 | 0 | 2 | 1 | 1 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Dose normalized maximum observed plasma concentration (Cmax)
| (ng/mL)/(mg) | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 0.281 (0.191 to 0.413) | 2.29 (1.46 to 3.59) | 2.74 (1.82 to 4.13) |
Time from dosing to Cmax, observed by inspection of individual subject plots of plasma concentration versus time.
| hour | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg, and APO-go 3 mg | 0.75 (0.52 to 0.75) | 0.38 (0.25 to 0.50) | 0.38 (0.25 to 0.50) |
| APL 25 mg, APOKYN 4 mg, and APO-go 4 mg | 0.63 (0.25 to 1.02) | 0.25 (0.25 to 0.25) | 0.26 (0.25 to 0.27) |
| APL 30 mg, APOKYN 5 mg, and APO-go 5 mg | 0.75 (0.50 to 1.00) | 0.38 (0.25 to 0.50) | 0.25 (0.25 to 0.50) |
area under the concentration-time curve from time zero to the last measurable plasma concentration-time curve using the linear up log down trapezoidal rule.
| (hxng/mL)/(mg) | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| Area Under the Concentration- Time Curve (AUC Last) | 0.500 (0.344 to 0.726) | 2.91 (1.97 to 4.30) | 3.00 (2.05 to 4.39) |
area under the concentration-time curve from time zero extrapolated to infinity using the linear up log down trapezoidal rule.
| (hxng/mL)/(mg) | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| Area Under the Concentration- Time Curve (AUC Inf) | 0.52 (0.36 to 0.76) | 2.97 (2.01 to 4.39) | 3.04 (2.08 to 4.45) |
Mean residence time during one dosing interval calculated using the following equation: MRT = AUMCinf/AUC inf. AUMCinf is the area under the first moment (time.plasma concentration vs. time) curve.
| h | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg, and APO-go 3 mg | 1.69 ± 5.2 | 1.44 ± 4.3 | 1.21 ± 19.3 |
| APL 25 mg, APOKYN 4 mg, and APO-go 4 mg | 1.83 ± 41.5 | 1.70 ± 13.8 | 1.51 ± 19.0 |
| APL 30 mg, APOKYN 5 mg, and APO-go 5 mg | 2.15 ± 15.9 | 1.23 ± 3.4 | 1.08 ± 35.4 |
Metabolite (apomorphine sulfate) to Parent exposure ratio, Cmax, corrected for molecular weight differences.
| no unit | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 61.6 ± 28.8 | 15.2 ± 48.9 | 11.5 ± 4.0 |
| APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 32.0 ± 157.1 | 9.0 ± 149.3 | 7.1 ± 240.3 |
| APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 61.2 ± 87.0 | 13.7 ± 8.2 | 11.3 ± 47.6 |
Apparent total clearance of the drug from plasma extravascular administration, calculated as Dose/AUCinf.
| L/h | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 2766.9 ± 52.4 | 407.9 ± 33.3 | 375.6 ± 32.2 |
| APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 1097.8 ± 99.5 | 250.2 ± 140.6 | 253.7 ± 169.6 |
| APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 1952.1 ± 44.3 | 350.6 ± 4.0 | 299.2 ± 41.0 |
Apparent volume of distribution after extravascular administration, calculated as Dose/(AUCinf \* λz).
| L | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 4440.2 ± 72.0 | 577.5 ± 44.3 | 469.3 ± 19.1 |
| APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 1733.4 ± 52.8 | 420.8 ± 193.7 | 372.2 ± 231.1 |
| APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 3419.5 ± 67.4 | 452.0 ± 14.7 | 324.2 ± 73.7 |
Terminal phase half-life, as calculated by the following equation: t½ = ln(2)/λz.
| h | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 1.11 ± 15.6 | 0.98 ± 9.9 | 0.87 ± 12.6 |
| APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 1.09 ± 34.3 | 1.17 ± 20.6 | 1.02 ± 19.7 |
| APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 1.21 ± 20.5 | 0.89 ± 18.7 | 0.75 ± 35.5 |
Apparent terminal elimination rate constant, determined by log linear regression of the plasma concentration versus time data that was judged to be in the log-linear elimination phase. At least 3 data points in the terminal phase will be used in the determination of the rate constant.
| /h | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 0.62 ± 15.6 | 0.71 ± 9.9 | 0.80 ± 12.6 |
| APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 0.63 ± 34.3 | 0.59 ± 20.6 | 0.68 ± 19.7 |
| APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 0.57 ± 20.5 | 0.78 ± 18.7 | 0.92 ± 35.5 |
Metabolite (apomorphine sulfate) to Parent exposure ratio, AUClast, corrected for molecular weight differences.
| no unit | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 98.16 ± 6.4 | 36.22 ± 3.0 | 32.19 ± 9.9 |
| APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 45.79 ± 169.9 | 18.70 ± 162.8 | 16.27 ± 221.6 |
| APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 98.07 ± 55.4 | 33.63 ± 6.2 | 26.22 ± 43.6 |
Collected over 16 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| APL-130277, Sublingual Thin Film | 0/8 (0%) | 1/8 (12.5%) | 1/8 (12.5%) |
| Subcutaneous APOKYN | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Subcutaneous APO-go | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 1/8 | 0/7 | 0/8 |
| Rib fractureInjury, poisoning and procedural complications | 1/8 | 0/7 | 0/8 |
| Splenic ruptureInjury, poisoning and procedural complications | 1/8 | 0/7 | 0/8 |
| Event | APL-130277, Sublingual Thin Film | Subcutaneous APOKYN | Subcutaneous APO-go |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/8 | 1/7 | 2/8 |
| SomnolenceNervous system disorders | 0/8 | 1/7 | 0/8 |
| Injection site bruisingGeneral disorders | 0/8 | 0/7 | 1/8 |
| DyskinesiaNervous system disorders | 0/8 | 0/7 | 1/8 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/8 | 0/7 | 1/8 |
| Age, Categorical(Participants) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 1 | 1 | 0 | 0 | 1 | 3 |
| >=65 years | 1 | 0 | 1 | 1 | 1 | 1 | 5 |
| Age, Continuous(Years) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 75 | 51 | 67.5 ± 9.19 | 67 | 73 | 68.5 ± 9.19 | 67.3 ± 8.7 |
| Sex: Female, Male(Participants) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Male | 1 | 0 | 2 | 1 | 1 | 1 | 6 |
| Ethnicity (NIH/OMB)(Participants) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 2 | 1 | 1 | 2 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 1 | 2 | 1 | 1 | 2 | 8 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Country(Participants) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| United States | 1 | 1 | 2 | 1 | 1 | 2 | 8 |
| Height (cm) at Baseline(cm) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 172.7 | 157.5 | 174.95 ± 11.243 | 175.3 | 177.8 | 171.25 ± 19.445 | 171.96 ± 10.545 |
| Body Weight (kg) at Baseline(kg) | APL-130277, Then APOKYN, Then APO-go | APL-130277, Then APO-go, Then APOKYN | APOKYN, Then APL-130277, Then APO-go | APOKYN, Then APO-go, Then APL-130277 | APO-go, Then APL-130277, Then APOKYN | APO-go, Then APOKYN, Then APL-130277 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 86.3 | 59.4 | 86.7 ± 20.506 | 73 | 84.4 | 71.2 ± 25.032 | 77.36 ± 15.895 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Mar 2019, 18 months.
Results were first posted in Aug 2020, 1 year 5 months after primary completion. A results delay was requested in Nov 2019.
Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 18 months is close to that.
Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apomorphine
Sumitomo Pharma America, Inc. →